Dexamethasone prevents granulocyte-macrophage colony-stimulating factor-induced nuclear factor-kappaB activation, inducible nitric oxide synthase expression and nitric oxide production in a skin dendritic cell line. by Vital, Ana Luísa et al.
AIMS: Nitric oxide (NO) has been increasingly im-
plicated in inflammatory skin diseases, namely in
allergic contact dermatitis. In this work, we investi-
gated the effect of dexamethasone on NO production
induced by the epidermal cytokine granulocyte 
/
macrophage colony-stimulating factor (GM-CSF) in a
mouse fetal skin dendritic cell line.Methods: NO
production was assessed by the method of Griess.
Expression of the inducible isoform of nitric oxide
synthase (iNOS) protein was evaluated by western
blot analysis and immunofluorescence microscopy.
Western blot analysis was also performed to evaluate
cytosolic IkappaB-alpha (IkB-a) protein levels. The
electrophoretic mobility shift assay was used to
evaluate the activation or inhibition of nuclear factor
kappa B (NF-kB).Results: GM-CSF induced iNOS ex-
pression and NO production, and activated the
transcription factor NF-kB. Dexamethasone inhib-
ited, in a dose-dependent manner, NO production
induced by GM-CSF. Addition of dexamethasone to
the culture, 30 min before GM-CSF stimulation, sig-
nificantly inhibited the cellular expression of iNOS.
Dexamethasone also inhibited GM-CSF-induced NF-
kB activation by preventing a significant decrease on
the IkB-a protein levels, thus blocking NF-kB migra-
tion to the nucleus.Conclusions: The corticosteroid
dexamethasone inhibits GM-CSF-induced NF-kB acti-
vation, iNOS protein expression and NO production.
These results suggest that dexamethasone is a potent
inhibitor of intracellular events that are involved on
NO synthesis, in skin dendritic cells.
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Introduction
Nitric oxide (NO), synthesized in large quantities by
the inducible isoform of NO synthase (iNOS), has a
dual role in human health, behaving as a ‘double
edge sword’. This free radical acts as a cytotoxic
agent against exogenous microorganisms, by stimu-
lating macrophage-induced inflammation and death
of infected cells. On the other hand, it favors
exaggerated tissue injury in sepsis, hypersensitivity
or autoimmunity, by promoting inflammation or
cytotoxicity of innocent bystander cells.
1 In the
skin, NO is produced by iNOS in several cells, namely
in keratinocytes, fibroblasts, Langerhans cells and
other dendritic cells. Apart from its potential bene-
ficial activity against external aggressors, it is increas-
ingly reported to be involved in skin inflammatory
and immune responses,
2,3 namely contact dermati-
tis,
4,5 both allergic contact dermatitis
6,7 and irritant
contact dermatitis,
6,8 atopic dermatitis,
9,10 and
psoriasis.
11 13 Among these diseases, which show a
good clinical response to topical glucocorticosteroids
(GCs),
14,15 a topical iNOS inhibitor has also been
shown to be effective in atopic dermatitis
10 and
psoriasis.
13
After stimulation by microorganisms and epidermal
cytokines, like interferon-g, tumor necrosis factor-a,
interleukin 1-b and granulocyte /macrophage col-
ony-stimulating factor (GM-CSF), Langerhans and
other dendritic skin antigen presenting cells produce
NO,
16 18 which may be important in the process of
antigen presentation to T cells.
19,20 We have pre-
viously shown, using a mouse fetal skin dendritic cell
line (FSDC) in culture, that GM-CSF, a cytokine
produced by allergen-stimulated keratinocytes that
promotes Langerhans cell maturation and antigen
presentation, induces NO production.
21 This is de-
pendent on the expression of iNOS and is associated
with the activation of the transcription nuclear factor
kappa B (NF-kB).
22 This transcription factor is pre-
sent in a latent (inactive) state in the cytoplasm,
bound to an inhibitor, IkappaB (IkB).
23 Exposure of
cells to a variety of physiological and non-physiolo-
gical stimuli induces phosphorylation, and subse-
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71quent degradation, of IkB protein.
24 This process
releases NF-kB from this inhibitor, enabling it to
translocate to the nucleus,
25 where it increases the
expression of specific genes, including those in-
volved in iNOS expression.
26,27
Glucocorticoids, which exert a multifunctional
anti-inflammatory activity in several skin diseases
and affect Langerhans cells maturation,
28 have been
shown, both in vivo and in vitro, to interfere with the
activity of iNOS and NF-kB in some pathological
processes and in some cell lines.
29 31 In this work,
we investigated the effect of dexamethasone on a
FSDC cell line stimulated by GM-CSF, evaluating NO
production, iNOS expression and NF-kB activation.
Our results showed that dexamethasone prevents
GM-CSF-induced reduction of the cytosolic levels of
the NF-kB inhibitor, IkB-a, and the subsequent
translocation of the NF-kB proteins into the nucleus,
where it is likely to mediate the observed inhibition
of iNOS expression and NO production.
Materials and methods
Materials
The rabbit anti-mouse iNOS polyclonal antibody was
purchased from Transduction Laboratories (Lexing-
ton, KY, USA) and the rabbit anti-IkB-a polyconal
antibody from New England BioLabs Inc. (Beverly,
MA, USA). The NF-kB consensus oligonucleotide was
from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), whereas the mouse monoclonal antibody
against actin and the protease inhibitor cocktail
were obtained from Roche (Carnaxide, Portugal).
The fluorescein isothiocyanate (FITC)-conjugated
swine anti-rabbit immunoglobulin was from DAKO
(Copenhagen, Denmark). The mounting medium for
fluorescence, Vectashield, was obtained from Vector
Laboratories, Inc. (Burlingame, CA, USA). The
32P-
labeled g-ATP, T4 polynucleotide kinase, poly(dI /
dC).poly(dI /dC), the ECL western blotting analysis
system, the horseradish peroxidase-conjugated don-
key anti-rabbit immunoglobulin and the X-ray films
were from Amersham Biosciences (Carnaxide, Portu-
gal). The horseradish peroxidase-conjugated goat
anti-mouse immunoglobulin was from Pierce (Rock-
ford, IL, USA). The mouse rGM-CSF was from R&D
systems (Minneapolis, MN, USA), fetal calf serum was
from Biochrom KG (Berlin, Germany) and trypsin
was from Invitrogen (Paisley, UK). Dexamethasone
was obtained from Sigma-Aldrich Quı ´mica (Sintra,
Portugal). Triton†X 100 and paraformaldehyde were
from VWR International/Merck Eurolab (Lisboa, Por-
tugal). All other reagents were from Sigma Chemical
Co (St Louis, MO, USA).
Cell culture
The fetal mouse skin dendritic cell line FSDC, kindly
supplied by Dr G. Girolomoni (Laboratory of Im-
munology, Instituto Dermopatico dell’Imacolata,
IRCCS, Rome, Italy), is a skin dendritic cell precursor
with antigen presenting capacity.
32 The cells were
cultured in endotoxin free Iscove’s Modified Dulbec-
co’s Medium, supplemented with 10% (v/v) fetal calf
serum, 1% (w/v) glutamine, 3.02 g/l of sodium
bicarbonate, 100 mg/ml of streptomycin and 100 U/
ml of penicillin. For western blot and electrophoretic
mobility shift assay (EMSA) analysis, FSDC were
plated at 2 /10
6 cells/well, in six-well culture plates,
whereas for nitrite measurements the cells were
plated at 0.2 /10
6 cells/well, in 48-well culture
plates. For immunofluorescence analysis, FSDC cells
were grown on Lab-Tek chamber slides with a cover
(0.2 /10
6 cells/slide).
Nitrite measurement
The production of NO was accessed as the accumu-
lation of nitrite ( /NO
 
2 ) in the culture supernatants,
using a colorimetric reaction with the Griess reagent,
as described previously.
22 Briefly, cells were stimu-
lated with GM-CSF (100 ng/ml) for 48 h, alone
(control) or in the presence of increasing concentra-
tions of dexamethasone (0.0025 /1 mM), added to the
cell culture 30 min before GM-CSF. In another set of
experiments, the cells were incubated for 48 h with
the same concentrations of dexamethasone, in the
absence of other stimuli.
At 48 h, culture supernatants were collected and
diluted with equal volumes of the Griess reagent
(0.1% (w/v) N-(1-naphthyl) ethylenediamine dihy-
drochloride, 1% (w/v) sulfanilamide and 5% (w/v)
H3PO4). After 10 min incubation, the absorbance was
measured at 550 nm in an automated plate reader
(SLT Spectra; Salzburg, Austria). The nitrite concen-
tration was determined from a sodium nitrite stan-
dard curve.
Western blot analysis
For immunodetection of iNOS, cells were treated
with culture medium alone (control) or with GM-CSF
(100 ng/ml) for 24 h, in the absence or in the
presence of the corticosteroid dexamethasone (0.5
mM), added to the cell culture 30 min before the GM-
CSF. As a second control, cells were also treated with
dexamethasone (0.5 mM) alone for the same time
period. After treatment, cells were washed twice with
phosphate-buffered saline (PBS) and total cell lysates
were obtained after harvesting the cells in a sonica-
tion buffer containing 0.32 M sucrose, 10 mM Tris /
HCl (pH 7.5), 1 mM ethylenediamine tetraacetic acid
(EDTA), 1 mM dithiothreitol, 0.1 mM phenylmethyl-
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Then, the lysates were incubated on ice for 30 min
and sonicated to disrupt the cells. The protein
concentration was determined using the bicinchoni-
nic acid method.
For immunodetection of IkB-a, FSDC cells were
maintained in the culture medium alone (control) or
were treated with GM-CSF (100 ng/ml) for 15, 45 and
60 min. To evaluate the effect of dexamethasone,
cells were stimulated for 45 min with GM-CSF (100
ng/ml) after pre-incubation with dexamethasone (0.5
mM), for 30 min. Proteins of the cytosolic fraction
were obtained after harvesting the cells in 10 mM
NaCl, 3 mM MgCl2, 0.5% (v/v) Nonidet P-40, 1 mM
dithiothreitol, 10 mM Tris /HCl (pH 7.5), 0.1 mM
phenylmethylsulfonylfluoride and protease inhibitor
cocktail. The lysates were incubated on ice for 15
min, and the cytosolic proteins were isolated from the
supernatant obtained after centrifugation at 2300 /g
for 10 min. The supernatant containing the cytosolic
proteins was collected, and the protein concentration
was determined using the bicinchoninic acid solu-
tion.
Protein samples were separated on 10% (v/v) (for
iNOS detection) or 15% (v/v) (for IkB-a detection)
sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis, and transferred to a polyvinylidene difluor-
ide membrane. The membrane was blocked with 5%
(w/v) dry milk in Tris-buffered saline with 0.1% (v/v)
Tween 20 for 1 h. The levels of iNOS and IkB-a
proteins were detected using, respectively, a rabbit
polyclonal anti-mouse iNOS antibody (1:2000) and a
rabbit polyclonal anti-IkB-a antibody (1:1000) for 1 h,
followed by incubation with a horseradish perox-
idase-conjugated donkey anti-rabbit antibody
(1:5000). The immunocomplexes were visualized by
the enhanced chemiluminescence (ECL) method. To
demonstrate equivalent protein loading, the mem-
branes were stripped and reprobed with an anti-actin
antibody.
The blots were digitally generated using a HP
ScanJet 5p and processed in the Corel Photo-Paint
program.
Immunofluorescence microscopy
For immunofluorescence analysis, FSDC cells were
treated with culture medium alone (control) or with
GM-CSF (100 ng/ml) for 24 h, in the presence or in
the absence of the corticosteroid, dexamethasone
(0.5 mM), added to the cell culture 30 min before the
GM-CSF. The cells were then washed with PBS and
fixed with PBS containing 4% (w/v) sucrose and 4%
(w/v) paraformaldehyde for 15 min. FSDC were then
permeabilized in PBS containing 1% (v/v) Triton†X
100 for 10 min. Non-specific binding was blocked by
incubation of the cells with PBS supplemented with
normal swine serum (1:20) and 0.5% (w/v) bovine
serum albumin (BSA) for 45 min at room tempera-
ture. Cells were then incubated for 90 min at room
temperature, with a rabbit polyclonal antibody direc-
ted against mouse iNOS (10 mg/ml). After rinsing with
PBS the cells were incubated with FITC-conjugated
swine anti-rabbit immunoglobulin (1:40) in 0.5%
BSA /PBS for 45 min. The cells were rinsed again
and mounted with the mounting medium for fluo-
rescence Vectashield. Cells labeled with FITC-anti-
iNOS were photographed on a Zeiss Axioskop
microscope. Control experiments consisted of pro-
cessing the same preparations as described, except
for the omission of the primary antibody, and
resulted in no specific staining.
Electrophoretic mobility shift assay
FSDC cells were kept in the culture medium alone
(control), were incubated with dexamethasone (0.5
mM) or were treated with GM-CSF (100 ng/ml) for 15,
45 and 60 min. In another set of experiments, cells
stimulated for 45 min with GM-CSF (100 ng/ml) were
also incubated with dexamethasone (0.5 mM), added
to the culture 30 min before the GM-CSF. The cells
were then washed with PBS and lysed in 10 mM
NaCl, 3 mM MgCl2, 0.5% (v/v) Nonidet P-40, 1 mM
dithiothreitol, 10 mM Tris /HCl (pH 7.5), 0.1 mM
phenylmethylsulfonylfluoride and protease inhibitor
cocktail. The lysates were incubated on ice for 15 min
and centrifuged at 2300 /g for 10 min. The pellet
obtained was resuspended in 300 mM NaCl, 5 mM
MgCl2, 20% (v/v) glycerol, 1 mM dithiothreitol, 0.2
mM EDTA, 20 mM HEPES buffer (pH 7.5), 0.1 mM
phenylmethylsulfonylfluoride and protease inhibitor
cocktail, incubated on ice for 1 h and centrifuged at
12,000 /g for 20 min. The supernatant containing
the nuclear proteins was collected, and the protein
concentration was determined using the bicinchoni-
nic acid method.
The EMSA method used was similar to that
described previously
33 with slight modifications.
The probes consisted of a double stranded oligonu-
cleotide containing the consensus binding sequence
for NF-kB( 5 ?-AGT TGA GGG GAC TTT CCC AGG C-
3?) end-labeled with [g-
32P]ATP using T4 polynucleo-
tide kinase. Typical binding reactions consisted of 12
mg of nuclear extract, about 100,000 cpm of [g-
32P]-
labeled oligonucleotide and 100 mg/ml of poly(dI /
dC).poly(dI /dC) in a buffer containing 20 mM
HEPES (pH 7.9), 1 mM MgCl2, 4% (w/v) Ficoll 400,
0.5 mM dithiothreitol, 50 mM KCl, and 1 mg/ml of
BSA, and were incubated at room temperature for 45
min. Binding reactions were separated on 7% (v/v)
non-denaturing polyacrylamide gels, in a buffer
system containing 0.044 M Tris /Base (pH 8.0), 4.45
mM boric acid and 1 mM EDTA, at a constant voltage
of 150 V, for 2h 30 min at room temperature. The gels
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subjected to autoradiography.
In competition experiments, an excess of unla-
beled oligonucleotide (100 /) was added to the
nuclear extracts for 30 min before addition of
radiolabeled probe.
The blots were digitally generated using a HP
ScanJet 5p and processed in the Corel Photo-Paint
program.
Data analysis
Results are presented as mean9 /standard error of the
mean of the indicated number of experiments. Mean
values were compared using one-way analysis of
variance and the Bonferroni’s multiple comparison
test. The significance levels were *pB/0.05, **pB/
0.01 and ***pB/0.001.
Results
Dexamethasone inhibits NO production in GM-
CSF-stimulated FSDC in a dose-dependent
manner
We have previously reported that GM-CSF causes a
dose-dependent increase in nitrite concentration in
culture supernatants, reflecting an increase in NO
production by the FSDC.
22 In the present work, 100
ng/ml of GM-CSF was used, which was previously
shown to increase significantly NO production.
22
Cell stimulation with GM-CSF for 48 h significantly
increased nitrite production, from 2.79 /1.1 mM when
FSDC were incubated with culture medium alone to
4.29 /1.5 mM when FSDC were incubated with 100 ng/
ml of GM-CSF. To investigate the effect of the dose of
dexamethasone on GM-CSF-induced NO production,
the corticosteroid was added in increasing concen-
trations (0.0025 /1 mM) to the culture, 30 min before
stimulation with GM-CSF. Dexamethasone inhibited
nitrite production induced by GM-CSF in a dose-
dependent manner (Fig. 1), with an IC50 value of
3.2 /10
 3 mM, as calculated by the Hill plot. A
concentration of 0.5 mM dexamethasone, which
completely inhibited NO production, was used in
subsequent experiments to study its mechanism of
action. Dexamethasone, in the absence of GM-CSF
stimulation, had no effect on NO production (data
not shown).
Cellular viability was evaluated by the reduction of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide and by the Trypan blue assay, as described
previously.
21 The results indicated that there was no
significant toxicity of dexamethasone in the concen-
trations used (data not shown).
Dexamethasone inhibits iNOS protein
expression in FSDC stimulated with GM-CSF
Western blot analysis was used to characterize iNOS
protein levels in non-treated cells (control), in cells
treated with GM-CSF, in the presence or in the
absence of dexamethasone, and in cells treated
only with dexamethasone. As indicated in Fig. 2A,B,
control cells (i.e. non-activated cells) expressed a
residual level of iNOS protein (130 kDa) (lane 1). In
cells stimulated with GM-CSF, the expression of iNOS
protein was increased by 106% relative to control
cells (lane 2). In GM-CSF-stimulated cells treated with
dexamethasone, the expression of iNOS protein was
significantly inhibited, decreasing to 42% of the GM-
CSF-stimulated cell levels (lane 4) and to 85% of the
iNOS levels expressed by control cells. When the
effect of dexamethasone was tested alone, we
observed a reduction of iNOS expression to 68% of
the control, which did not reach statistical signifi-
cance (lane 3). This decrease in iNOS protein
expression correlated well with the inhibitory effect
of dexamethasone on NO production, as shown in
Fig. 1.
Immunofluorescence assay was performed to con-
firm these results, under the same conditions used for
western blot. Fig. 2C shows that control cells (i.e.
cells maintained in culture medium) expressed a
residual level of iNOS protein. In cells treated with
GM-CSF, the fluorescence was markedly increased,
showing a significant increase in iNOS protein
expression. GM-CSF-stimulated cells treated with
dexamethasone exhibited a similar, although weaker,
fluorescence than control. The fluorescence exhib-
FIG. 1. Dose-dependent effect of dexamethasone on GM-
CSF-induced nitrite production in FSDC. FSDC (0.2 /10
6
cells) were pre-treated for 30 min with a range of concentra-
tions of dexamethasone (0.0025 /1 mM), as indicated, and
then stimulated with 100 ng/ml GM-CSF for 48 h. Results
were expressed as percentage of maximal nitrite production
on the supernatants of cells maintained in culture medium,
in the presence of GM-CSF and in the absence of dexa-
methasone. Nitrite levels in the culture supernatants were
detected by the Griess reaction as described in Materials and
methods. Each value represents the mean9 /standard error of
the mean from ﬁve experiments.
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minimal, the weakest of all. All these results corre-
lated well with the results obtained in the western
blot assays (Fig. 2A).
Dexamethasone blocks the activation of NF-kB
in FSDC stimulated with GM-CSF
The effect of dexamethasone on NF-kB activation
induced by GM-CSF in FSDC cells was evaluated in
nuclear extracts by EMSA analysis. The cells were
incubated with GM-CSF for 15, 45 and 60 min to
determine the effect of cytokine on the activation of
NF-kB, or were pre-treated with dexamethasone for
30 min and then stimulated with GM-CSF for 45 min
in order to investigate the effect of the corticosteroid.
As shown in Fig. 3A,B, GM-CSF induced NF-kB
binding to DNA, exhibiting a maximal effect at 45
min when the NF-kB binding activity was increased
by 101% relative to control cells (lanes 2 and 4). Pre-
treatment with dexamethasone prevented NF-kB
binding to DNA in GM-CSF-stimulated cells. Fig.
FIG. 2. Effect of dexamethasone (Dex) on GM-CSF-induced iNOS protein expression in FSDC. (A) Western blot analysis of
iNOS and actin protein levels. FSDC cells (2 /10
6cells) were incubated for 24 h with culture medium alone (control, lane 1),
with 100 ng/ml of GM-CSF (lane 2), with 100 ng/ml of GM-CSF in the presence of 0.5 mM dexamethasone (lane 4), or with 0.5
mM dexamethasone alone (lane 3). When the effects of dexamethasone on the response to GM-CSF was investigated, the cells
were pre-incubated with the corticosteroid for 30 min. Total cell extracts were electrophoresed through sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, transferred to polyvinyl diﬂuoride membranes and subjected to western blot
analysis using an anti-iNOS antibody as described in Materials and methods. The membrane was stripped and reprobed with
anti-actin antibody to conﬁrm equal protein loading. The blot shown is representative of three blots yielding similar results.
(B) The results obtained in three independent experiments were quantiﬁed with an image analyzer and the results are
presented as means9 /standard error of the mean. ***pB/0.001, as determined by one-way analysis of variance with
Bonferroni’s multiple comparison test. (C) Immunoﬂuorescence analysis of iNOS protein. FSDC cells (0.2 /10
6) were
incubated under the same conditions as performed for western blot assay.
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dexamethasone for 30 min before stimulation with
GM-CSF for 45 min, in the presence of the corticos-
teroid, fully blocked GM-CSF-induced NF-kB binding
to DNA (lane 6). Under these experimental condi-
tions, NF-kB binding to DNA was decreased to 55% of
the activity found in GM-CSF-stimulated cells and was
not significantly different from the control. Dexa-
methasone alone had no effect on NF-kB binding to
DNA (10% of difference from the control) (lane 7).
As control for the gel shift assay, unlabeled
oligonucleotide (100-fold excess) was used (lane 8),
which inhibited the NF-kB complex formation.
Dexamethasone inhibition of NF-kB in GM-CSF-
stimulated FSDC is mediated by modulation of
cytosolic IkB-a levels
As we have previously shown, GM-CSF induces an
IkB-a degradation in FSDC.
22 To determine whether
the suppressive effect of dexamethasone on GM-CSF-
induced NF-kB activation was due to the modulation
of its inhibitor, IkB-a, the levels of this protein on
cytosolic cell extracts were examined by western blot
analysis.
As shown in Fig. 4A,B, we observed that GM-CSF
induced a maximal reduction in IkB-a protein levels
at 45 min, when a reduction in the protein levels to
44% of the control was observed (lanes 1 and 3). This
reduction was fully inhibited when FSDC were pre-
incubated with dexamethasone for 30 min and then
stimulated with GM-CSF for 45 min in the presence of
the corticosteroid (lane 5), where an increase of 93%
in IkB-a protein levels was observed comparative
with GM-CSF-stimulated cells in the absence of
dexamethasone. Indeed, the amount of IkB-a present
in FSDC stimulated with GM-CSF in the presence of
dexamethasone was not significantly different from
the protein levels in control cells. These results show
that there is a correlation between the inhibitory
FIG. 3. Effect of dexamethasone (Dex) on GM-CSF-induced NF-kB binding to DNA in FSDC. FSDC (2 /10
6cells) were incubated
in culture medium alone (control, lane 2) or in the presence of 100 ng/ml of GM-CSF, for 15, 45 and 60 min (lanes 3 /5). In lane
6 the cells were pre-incubated with 0.5 mM dexamethasone for 30 min before stimulation with GM-CSF and dexamethasone
for 45 min. Control experiments, where the cells were incubated with dexamethasone for 75 min, are shown in lane 7.
Unlabeled oligonucleotide (i.e. non-radioactive NF-kB consensus containing oligonucleotide) was used in excess (100-fold) to
demonstrate speciﬁcity of the induced bands (lane 8). (A) Nuclear extracts were subjected to EMSA analysis as described in
Materials and methods. The blot shown is representative of three blots yielding similar results. (B) The bands were quantiﬁed
with an image analyzer and the results are shown as means9 /standard error of the mean from three independent
experiments. **pB/0.01 and ***pB/0.001, as determined by one-way analysis of variance with Bonferroni’s multiple
comparison test.
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activation and on GM-CSF-induced IkB-a protein
down-regulation.
Discussion
The anti-inflammatory properties of GCs such as
dexamethasone are due to the down-regulation of
the expression of immunomodulatory genes,
26,30
thereby inhibiting the expression of enzymes in-
volved in the inflammatory process, namely iNOS,
which produces NO in large amounts.
29,34 GCs
mediate these effects through the intracellular gluco-
corticoid receptor and, depending on the target gene,
the complex ligand /glucocorticoid receptor may
stimulate (transactivation), or alternatively inhibit
(transrepression), gene transcription.
30,35 In this
work, we show that, in FSDC, the glucocorticoid
dexamethasone inhibits iNOS protein expression and
nitrite production induced by GM-CSF. Furthermore,
dexamethasone also prevents the decrease of IkB-a
protein levels, and subsequent NF-kB translocation to
the nucleus, induced by GM-CSF (Fig. 3 and Fig. 4).
NO has previously been involved in skin inflamma-
tory processes, namely in psoriasis,
11 allergic contact
dermatitis,
6,7 atopic dermatitis,
9 and other inflamma-
tory skin diseases,
2 where topical GCs have shown to
be beneficial.
GM-CSF is a multipotent cytokine that mediates the
development of immunologically active DC in
culture
36 38 and that is involved in inflammatory
processes.
37 In the skin, the epidermal cytokine GM-
CSF is produced by keratinocytes upon stimulation
by allergens and it promotes Langerhans cell matura-
tion, thus favoring antigen presentation to T cells.
39
Allergic contact dermatitis has an inflammatory
component, and therefore GM-CSF is probably in-
volved in this pathology.
In our previous work, we observed that, in FSDC,
GM-CSF induces iNOS protein expression and NO
production in a process dependent on the nuclear
migration of NF-kB, which occurs upon phosphor-
ylation and degradation of their cytosolic inhibitor,
IkB-a.
22 IkB-a protein is a member of a family of
inhibitory molecules that masks the nuclear localiza-
tion sequence of NF-kB, inhibiting its binding to
DNA.
24,25,40,41 Here, we demonstrated that, in FSDC
cells, dexamethasone prevents the decrease of cyto-
solic IkB-a protein levels induced by GM-CSF (Fig.
4), and inhibits NF-kB binding to DNA (Fig. 3). In
contrast, activated NF-kB may then bind to the iNOS
gene promoter region, thereby stimulating iNOS
protein expression. Accordingly, the promoter region
of the iNOS gene contains binding sites for the NF-
kB.
23
The induction of allergic responses by chemical
sensitizers encountered on the skin is dependent
upon the action of cytokines produced locally.
37
These skin cytokines may also serve to influence
the inflammatory and immune responses provoked
by chemical sensitizers and, concomitantly, the
characteristics of allergic diseases.
37 The anti-inflam-
matory proprieties of glucocorticoids on iNOS ex-
pression and NO production induced by the
epidermal cytokine GM-CSF had not been described
before. The results presented here show that the
inhibitory effect of dexamethasone on GM-CSF-
induced iNOS expression and NO production can
account for the anti-inflammatory effect of this
glucocorticoid.
A better knowledge of the signaling pathways
activated in DC that induce iNOS expression and
the mechanism of action of drugs, like GCs, useful in
the treatment of cutaneous inflammatory processes,
FIG. 4. Effect of dexamethasone (Dex) on GM-CSF-stimulated
IkB-a decrease in FSDC. FSDC (2 /10
6cells) were incubated
in culture medium alone (control, lane 1) or in the presence
of 100 ng/ml of GM-CSF for 15, 45 and 60 min (lanes 2 /4).
Lane 5 corresponds to cells pre-incubated with 0.5 mM
dexamethasone for 30 min before the stimulation with 100
ng/ml of GM-CSF for 45 min. Cytosolic cell extracts were
electrophoresed through sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis, transferred to polyvinyl diﬂuor-
ide membranes and subjected to immunoblot analysis using
an anti-IkB-a antibody as described in Materials and meth-
ods. The membrane was stripped and reprobed with an anti-
actin antibody to conﬁrm equal protein loading. (A) Western
blot analysis of IkB-a and actin protein levels. The blot
shown is representative of three blots yielding similar
results. (B) The bands were quantiﬁed with an image
analyzer and the results are shown as means9 /standard
error of the mean from three independent experiments.
***pB/0.001, as determined by one-way analysis of variance
with Bonferroni’s multiple comparison test.
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diseases and their treatment.
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